Tumor necrosis factor-a (TNF-a) and ®broblast growth factor-2 (FGF-2 or bFGF) are potent stimulators of angiogenesis. TNF-a, but not FGF-2, can induce the expression of vascular cell adhesion molecule-1 (VCAM-1) on the surface of endothelial cells. The soluble form of VCAM-1 has recently been demonstrated to function as an angiogenic mediator. Here we demonstrate that monoclonal antibodies directed against VCAM-1 or its a4 integrin counter-receptor inhibited TNF-a-induced endothelial cell migration in vitro. Angiogenesis induced in vivo in rat corneas by TNF-a was inhibited by a neutralizing antibody directed against the rat a4 integrin subunit. A peptide antagonist of the a4 integrins blocked TNF-a-induced endothelial cell migration in vitro and angiogenesis in rat corneas in vivo. No inhibition by the antibodies or peptide antagonist was observed either in vitro or in vivo when FGF-2 was used as the stimulus. The peptide antagonist did not inhibit TNF-a binding to its receptor nor did it block the function of avb3, an integrin previously implicated in TNF-a and FGF-2 mediated angiogenesis. These results demonstrate that angiogenic processes induced by TNF-a are mediated in part by a4 integrins possibly by a mechanism involving the induction of soluble VCAM-1.
Introduction
Angiogenesis is the growth of new blood vessels from preexisting vessels. This process is essential for proper development and wound healing, yet is also characteristic of certain pathological conditions including arthritis, psoriasis, retinopathy and tumor growth.
1 TNF-a is one of the primary angiogenic mediators derived from activated macrophages and as such is thought to play a key role in chronic in¯ammatory diseases such as rheumatoid arthritis. 2 TNF-a was ®rst identi®ed as the substance mediating necrosis of certain tumors that were treated with endotoxin. 3 Although TNF-a inhibits endothelial cell growth in vitro, 4, 5 it has been shown to induce endothelial cell migration in vitro 6 and cause angiogenesis in vivo when implanted into corneas or choriallantoic membranes. 5, 6 It has been proposed that the mechanism of TNF-a mediated angiogenesis may be indirect and may depend on the synthesis of secondary mediators including prostaglandins, platelet activating factor, the Eck receptor ligand B61, and more recently interlukin-8, vascular endothelial growth factor (VEGF) and FGF-2.
E-selectin, on the surface of endothelial cells. 12, 13 Soluble forms of VCAM-1 (sVCAM-1) and E-selectin have recently been demonstrated to function as angiogenic mediators. 14 The a4 integrins serve as counter-receptors for VCAM-1. 15, 16 Expressed abundantly on the surface of leukocytes, the a4 integrin subunit has been detected at lower levels on the surface of endothelial cells as well. 14, 17 In fact, neutralizing antibodies directed against the a4 integrin receptors inhibit the migration of endothelial cells toward sVCAM-1. 14 We have used endothelial cell migration assays and an in vivo model of angiogenesis to demonstrate that TNF-a-induced angiogenesis is dependent, in part, on functions mediated by a4 integrins. These data implicate sVCAM-1 as a potential secondary mediator in angiogenic processes induced by TNF-a.
Materials and methods
Materials. Recombinant human TNF-a and recombinant human FGF-2 were purchased from R&D Systems, Inc. (Minneapolis, MN) and Upstate Biotechnology (Lake Placid, NY), respectively. Anti-human VCAM-1 was from Genzyme (Cambridge, MA) and anti-rat a4 (TA-2) was from Seikagaku America, Inc. (Rockville, MD). Anti-human a4 (L25) and anti-human b1 (mAb13) were from Becton Dickinson (San Jose, CA). Anti-human b1 (33B6) and anti-Leu 13 (35F9) were generated and maintained in the McIntyre laboratory. Anti-CD3 mAb OKT3 was obtained from the American Type Culture Collection (Rockville, MD). Anti-human avb3 (23C6) was from Pharmingen (San Diego, CA). Anti-human avb5 (P1F6) ascites and the cyclic RGD peptide (GPenGRGDSPCA) were from Life Technologies (Grand Island, NY Migration assays. Assays were carried out in a 48-well chamber (NeuroProbe, Cabin John, MD) using collagen coated polycarbonate ®lters following procedures similar to those previously described. 19 Brie¯y, polycarbonate ®lters (8 lm pore size; Poretics Corp., Livermore, CA) were treated with 0.5 M acetic acid overnight, rinsed with distilled water, and incubated for 48 h at room temperature with 10 lg/ml collagen (Vitrogen 100; Cetrix Laboratories; Palo Alto, CA). Filters were air dried prior to placing into the chamber. Subcon¯uent HUVEC (passage 1±4) were harvested with 0.05% trypsin/EDTA, washed with M199 containing 10% fetal calf serum and resuspended in M199 containing 0.1% FCS at 5´10 5 cells/ml. TNF-a at 50 ng/ml or FGF-2 at 10 ng/ml in M199/0.1% FCS was placed in the bottom wells of the chamber and 150 ll of HUVEC (75,000 cells) were placed in the upper wells. Antibodies (10 lg/ml) or peptides (10 lM) were added to both the top and bottom chambers.
The chamber was incubated for 4 h at 37°C in a 5% CO 2 incubator. Solution in the top wells was aspirated and nonmigrated cells were removed from the ®lter with a wet cotton swab. Migrated cells were ®xed in 100% ethanol for 30 min at room temperature and stained with a modi®ed Wright-Giemsa stain (Diff-Quik, Baxter Diagnostics, Chicago, IL). Migrated cells were counted at 400´magni®cation in four random ®elds per well. Each treatment group was performed in triplicate wells. Statistical analysis of the data was performed using a paired Student's t-test with p < 0.05 considered statistically signi®cant.
Flow Cytometry. HUVEC were harvested as described above and resuspended in RPMI 1640 supplemented with 10% FCS (3´10 6 cells/ml). mAbs (0.1 lg/ml) were added and incubated for 30 min at room temperature. Cells were washed twice with PBS containing 1% BSA and incubated with goat anti-mouse FITC for 30 min at room temperature. Cells were washed with PBS and analyzed in an EPICS Pro®le¯ow cytometer (Coulter Corp., Hialeah, FL). At least 10,000 events were analyzed for every test.
Quanti®cation of soluble VCAM-1. Con¯uent monolayers of HUVEC in 35 mm plates were treated with 50 ng/ml TNF-a or 10 ng/ml FGF-2 in M199/0.1% FCS for 4 h at 37°C. Media was collected, centrifuged for 5 min at 1000´g, and concentrated using Centricon-3 ®lters (Amicon, Beverly, MA). Samples were assayed for the presence of human soluble VCAM-1 using an immunoassay kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Corneal angiogenesis assays. Assays were performed similarly to those previously described. 6 Pellets were made by mixing equal volumes of TNF-a or FGF-2 (300 ng in PBS containing 0.1% BSA) and a 12% solution of Hydron (Interferon Sciences, New Brunswick, NJ) in ethanol. Antibodies (1.75 lg/pellet) or peptides (100 ng/ pellet) were added directly to the cytokine/hydron solution. Five ll were placed on the ends of 2 mm diameter te¯on rods and allowed to dry for 30 min in a cell culture hood. Pellets were implanted in the corneas of 300±400 g SpragueDawley rats approximately 1 mm from the limbus. After 7 days, rats were euthanized with CO 2 , the vasculature perfused with buffer (PBS containing 10 U/ml heparin) followed by colloidal carbon, and eyes excised and ®xed in 10% formalin.
TNF-a receptor assay. Anti-Human TNF Receptor (p55) IgG (Austral Biologics, San Ramon, CA) was coated onto Immulon-4 plates at 1 lg/well in PBS overnight at 4°C. Wells were washed three times with PBS containing 0.1% Tween-20 followed by three washes with PBS. Wells were blocked with 1% BSA in PBS for 1 h at 22°C and then washed as described above. Recombinant human TNF-a receptor extracellular domain (Austral Biologics) was coated onto the wells at 10 ng/well in PBS overnight at 4°C. Wells were washed, blocked and rewashed as described above.
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I-TNF-a (Biomedical Technologies Inc., Stoughton, MA) in PBS containing 0.1% BSA and 25 mM HEPES was added to the wells at a concentration of 300 pg (2´10 4 cpm)/well. In certain wells, unlabeled TNF-a (300 ng/well, PeproTech Inc., Rocky Hill, NJ) or TBC772 (1 mM) were also added. Plates were incubated for 90 min at 22°C and washed three times with PBS. Wells were separated, placed in vials containing scintillation¯uid and counted using a Beckman LS6000TA scintillation counter. avb3 assay. Human plasma vitronectin was coated onto 96-well Probind plates at 5 lg/ml in TBS (50 mM Tris, pH 7.5, 150 mM NaCl) for 16 h at 4°C. Control wells were coated with the same concentration of BSA in TBS. Plates were washed three times with TBS, blocked with TBS containing 2% BSA at room temperature for 4 h, then washed three more times with TBS prior to assay. HUVEC grown to con¯uency were harvested as described above and resuspended in M199 containing 0.1% BSA. Cells were¯uores-cently labeled with calcein AM (Molecular Probes, Eugene, OR) and resuspended at 4´10 6 E-selectin assay. Assays were performed as previously described. 20 Brie¯y, 10 ll of¯uorescently labeled HL-60 cells (10 7 cells/ml) were added to wells of a 96 well plate that had been previously blocked with 3% BSA. This was followed by the addition of 10 ll of magnetic beads (4´10 6 beads/ml) coated with an E-selectin IgG fusion protein. After a 10 min incubation at room temperature, the beads were placed on a magnetic seperator and unbound cells were removed with two washes of the wells with PBS. Bound cells were lysed with a 1% NP-40 solution in PBS and quantitated using a Millipore Cyto¯uor 2350 uorimeter. The TBC772 peptide was added to the cells immediately prior to the addition of beads. Binding of HL-60 cells to E-selectin beads previously has been shown to be blocked by sLe x tetrasaccharide and anti-sLe x antibodies. 20 
Results
Inhibition of a4 integrins or VCAM-1 inhibits TNF-aA but not FGF-2-induced endothelial cell migration. HUVEC migration across collagen coated polycarbonate membranes was measured in response to the cytokines TNF-a or FGF-2. The optimal doses for HUVEC migration were determined to be 50 ng/ml and 10 ng/ml for TNFa and FGF-2, respectively (data not shown). Stimulation with cytokines resulted in an $1. In each case, the y-axis represents a two-fold range of cell counts. Statistical analysis of the data was performed using a paired student's t-test with p < 0.05 considered statistically signi®cant (n.s. not signi®cant).
TNF-a-induced migration was inhibited greater than 75% in the presence of an anti-VCAM-1 antibody (p 0.007 relative to an isotype control) ( Figure 1A) . Similarly, HUVEC migration in response to TNF-a was completely inhibited in the presence of an anti-a4 antibody (p 0.025 relative to an isotype control) (Figure 1B) . Signi®cant inhibition of migration also was demonstrated with a cyclic peptide antagonist of a4 integrins, TBC772, 18 included in the assay at a concentration of 10 lM (p 0.023 relative to a scrambled peptide control TBC1194) (Figure 1C) . In contrast, no signi®cant inhibition of FGF-2-induced HUVEC migration was seen relative to controls in the presence of anti-VCAM-1, anti-a4 or TBC772 (Figures 1A±C).
HUVEC treated with TNF-a generate sVCAM-1.
The above results suggested that HUVEC migration induced by TNF-a may be mediated by the interaction between VCAM-1 and its a4 integrin counter-receptor. TNF-a induces VCAM-1 expression on the surface of endothelial cells 12 whereas FGF-2 does not. 21 Since a soluble form of VCAM-1 previously has been demonstrated to induce endothelial cell migration, 14 levels of sVCAM-1 in culture media from cells treated with TNF-a were determined. Conuent monolayers of HUVEC in 35 mm plates were treated with cytokines under the same conditions used in the migration assays (4 h at 37°C with 50 ng/ml TNF-a or 10 ng/ml FGF-2). Culture media were collected and assayed for the presence of sVCAM-1 by ELISA. No sVCAM-1 was detected in media derived from untreated cells or cells treated with FGF-2. sVCAM-1 was detected in media from TNF-a treated cells at a concentration of 1.76 0.06 ng/ml or $20 pM.
Although a4 integrin has previously been reported to be expressed on the surface of HU-VEC, 14 ,17 the presence of a4 on the HUVEC used for the experiments described herein was veri®ed by¯ow cytometry. Figure 2 shows the relativē uorescence intensity pro®les obtained with HUVEC in the presence of various antibodies. The pro®les of HUVEC with mAbs directed against the leukocyte antigens CD3 (OKT3) (2.8% positive cells) or Leu 13 (35F9) (3.1% positive) served as negative controls and were essentially indistinguishable from that of FITC alone (2.2% positive). In contrast, there was a signi®cant shift in the pro®le with a mAb against the a4 integrin subunit (L25) (28.1% positive). The anti-b1 mAb, 33B6, was used as a positive control (84.2% positive). These results demonstrate that a4 integrin receptors are indeed expressed on the surface of the HUVEC that were used for the experiments detailed above.
Inhibition of a4 integrins inhibits TNF-aA but not FGF-2-induced angiogenesis in the rat cornea.
The rat corneal model was used to determine if a4 integrins were involved in TNF-a-induced angiogenesis in vivo. Hydron pellets containing cytokines and either an anti-rat a4 integrin monoclonal antibody or an IgG1 control were implanted into rat corneas and analyzed 7 days later following perfusion of the blood vessels with India ink. The anti-a4 antibody blocked the angiogenic response induced by TNF-a in all six corneas tested (0 of 6 corneas were positive) whereas the control IgG1 had a negligible effect on the angiogenic response (7 of 9 corneas posi- tive) ( Figure 3A , Table 1 ). Similar results were obtained with the a4 peptide antagonist and control; angiogenesis induced by TNF-a was effectively inhibited with TBC772 (0 of 8 corneas positive) but not with the control peptide TBC1194 (7 of 8 corneas positive) ( Figure 4A , Table 1 ). Conversely, neither the anti-rat a4 antibody nor TBC772 were effective inhibitors of angiogenesis induced by FGF-2 ( Figures 3B, 4B and Table 1 ). The antagonist peptide did not prevent angiogenesis by non-speci®cally inhibiting TNF-a binding to its receptor; since no inhibition was detected in a TNF-a receptor binding assay at concentrations as high as 1 mM TBC772 ( Figure 5A ). TNF-a-induced angiogenesis has been shown to be dependent on the integrin avb3.
11 Although the peptide TBC772 is selective for the a4 integrins over a5b1, 18 an assay was developed to determine if the peptide demonstrated any activity towards avb3. The binding of HU-VEC to human plasma vitronectin was determined to be inhibited by an anti-avb3 antibody (p 0.0008) and completely eliminated by a cyclic RGD peptide speci®c for the vitronectin receptor at a concentration of 10 lM (p 0.0001) ( Figure 5B ). No inhibition of avb3-dependent binding of HUVEC to vitronectin was detected in the presence of 1 mM TBC772 ( Figure 5B) .
Finally, TNF-a induces the expression of E-selectin on the surface of endothelial cells. 13 A soluble form of E-selectin has also been demonstrated to function as an angiogenic mediator with sLe x being the likely counter-receptor. 14 As an additional analysis of speci®city, TBC772 at 1 mM had no effect on the binding of sLe x -expressing HL-60 cells to puri®ed E-selectin (FigFigure 3 . Angiogenesis induced in rat corneas by TNF-a is inhibited by an anti-rat a4 antibody. Hydron pellets containing 300 ng of TNF-a (A) or FGF-2 (B) were implanted into the corneas of Sprague-Dawley rats. Pellets also contained anti-rat a4 antibody or an IgG1 isotype control antibody (1.75 lg/pellet) as indicated. Seven days later, rats were perfused with colloidal carbon and the eyes excised and ®xed. ure 5C). The binding of the HL-60 cells to the Eselectin in this assay format has previously been shown to be blocked by sLe x tetrasaccharide and anti-sLe x antibodies. 20 A summary of the activity of TBC772 in various adhesion assays is given in Table 2 . Although the peptide antagonist is quite selective for the a4 class of integrins, the possibility remains that it may be active in the migration and corneal assays by interacting with other endothelial cell adhesion molecules or receptors yet to be analyzed.
Discussion
TNF-a is a pluripotent mediator effecting several cellular processes including adhesion, migration, angiogenesis and apoptosis. 6, 12, 22 The angiogenic potential of TNF-a may be due to the generation Figure 5 . TBC772 does not inhibit ligand binding to the TNF receptor, avb3, or E-selectin. All assays were performed as described in`Materials and methods'. Statistical analysis of the data in Figures 5A and 5B was performed using a paired Student's t-test. Treatment groups with p values less than 0.05 when compared to untreated controls were considered statistically signi®cant and denoted with an asterisk (*). (A) [
125 I] TNF-a binding to recombinant human TNF-a receptor extracellular domain was measured in the absence or presence of unlabeled TNF-a or 1 mM TBC772. TNF-a binding is expressed as the average cpm SD of duplicate wells. (B) Binding of uorescently labeled HUVEC to human plasma vitronectin immobilized on a 96 well plate was measured in the absence or presence of 10 lM RGD peptide (GpenGRGDSPCA), 1 mM TBC772, anti-avb3 (10 lg/ml), anti-b1 (10 lg/ml), anti-avb5 ascites (1:100 dilution) or the proper isotype controls. The data are expressed as % adhesion relative to untreated HUVEC bound to vitronectin (typically 1600 cells bound/mm 2 ) versus bound to BSA (typically <10 cells bound/mm 2 ). The data represent the average % adhesion SD of triplicate wells. (C) Binding of¯uorescently labeled HL-60 cells to an E-selectin-IgG fusion protein bound to magnetic beads was measured in the absence or presence of 1 mM TBC772. Background¯uores-cence of control mock beads ($10% of E-selectin beads) was subtracted from all values. The binding of the HL-60 cells to the E-selectin in this assay format previously has been shown to be blocked by sLe x tetrasaccharide and anti-sLe x antibodies. 20 The data represent the average number of cells bound per well SD of duplicate wells. x /E-selectin >1000 This paper a The cell adhesion assays measure the binding of integrin-or sLe x -expressing cell lines to puri®ed forms of the counter-receptors. All cell lines and counter-receptors are of human origin except the a4b7-expressing cell line and the MAdCAM-1 which are both of murine origin. IC 50 values represent the concentration of compound required for inhibition of maximal cell binding by 50%.
b of secondary mediators, including prostaglandins, 7 platelet activating factor, 8 the ligand for the Eck receptor tyrosine kinase, B61 9 as well as interlukin-8, VEGF and FGF-2. 10 The data presented here suggest that sVCAM-1 may also play a key role in TNF-a-induced angiogenesis.
Using endothelial cell migration assays as well as a rat corneal angiogenesis assay, we have demonstrated a role for the VCAM-1/a4 integrin pathway in TNF-a-mediated angiogenesis. HU-VEC treated with TNF-a generated concentrations of sVCAM-1 ($20 pM) previously shown to induce signi®cant levels of endothelial cell migration.
14 Antibodies directed against VCAM-1 and the a4 integrin subunit signi®cantly inhibited the migration of HUVEC across collagen coated ®lters in response to TNF-a. In vivo, antibodies directed against rat a4 integrin effectively blocked TNF-a-induced angiogenesis in rat corneas. A peptide antagonist selective for the a4 integrins was also found to inhibit both HUVEC migration in vitro and corneal angiogenesis in vivo mediated by TNF-a. These data support the hypothesis that TNF-a can mediate angiogenic processes by inducing the production of sVCAM-1 from endothelial cells which can then function as an angiogenic stimulus via interaction with an a4 integrin counter-receptor on the endothelium.
Integrins, including avb3, have been clearly linked to TNF-a-induced angiogenesis. 11 How might the a4 integrins also be involved in regulating this process? sVCAM-1 binding to a4 integrin receptors on endothelial cells may lead to integrin-dependent signaling pathways regulating chemokinetic or chemotactic mechanisms. Here we show that inhibitors of the a4 integrins can inhibit the migration of HUVEC across collagen coated membranes. This class of integrins do not bind collagen suggesting an indirect role for the a4 integrins in this process. Recent reports have demonstrated that the engagement of one integrin can regulate the function of another in several diverse settings.
23±27 Antibodies to avb3 have been shown to block a5b1-dependent phagocytosis. 23 T cell coactivation induced by either b2 or b7 integrins could be inhibited by an anti-b1 antibody. 24 Engagement of aIIbb3 inhibited the adhesive functions of the integrins a2b1 or a5b1 in transfected chinese hamster ovary cells. 25 Finally, ligation of LFA-1 on T-cells was found to regulate a4b1 and a5b1-mediated adhesion. 26 Migration of endothelial cells, a critical component of angiogenesis, is a complex process involving a series of integrin-mediated adhesion and de-adhesion events. Engagement of a4 integrins by sVCAM-1 may lead to cross-talk with other key integrins and play a role in coordinating these events. In fact, cross-talk between avb3 and a4b1 has recently been demonstrated in the regulation of lymphocyte migration on VCAM-1.
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Angiogenesis is also characterized by the production and activation of proteinases. Huhtala et al. 28 have demonstrated in rabbit synovial ®broblasts that the ligation of a4b1 can regulate the expression of matrix metalloproteinases induced by the interaction of the integrin a5b1 with ®bronectin. Additionally, TNF-a induces the expression of urokinase plasminogen activator by endothelial cells which may promote angiogenesis. 29 The urokinase receptor has been demonstrated to associate with and regulate the function of certain integrins. 30 Reciprocally, integrins associated with the urokinase receptor, a glycosyl-phosphatidylinositol-linked protein, may serve as a means for urokinase receptor signal transduction. In this regard, it is important to note that it has yet to be determined if a4 integrins are associated with the urokinase receptor on endothelial cells. At the level of migration and proteolysis, the a4 integrins may be involved at several key steps in regulating angiogenesis induced by TNF-a. Further research is required to dissect the molecular details of such a mechanism.
The a4 integrins and/or their ligands have been implicated in several in¯ammatory disease states. 31 Monoclonal antibodies to the a4 subunit have proven to be effective treatments in animal models of asthma, 32 multiple sclerosis, 33 diabetes, 34, 35 in¯ammatory bowel disease, 36 coronary allograft rejection 37 and rheumatoid arthritis. 38, 39 Presumably these treatments have been successful by either preventing the adhesion and subsequent migration of in¯ammatory cells or by inhibiting activation of cell types critical for the progression of the in¯ammatory cascade. The data reported here suggest an additional mechanism by which an a4 integrin antagonist may be functioning in those in¯ammatory diseases that contain an an-giogenic component. For example, rheumatoid arthritis is characterized not only by in®ltration of in¯ammatory cells into the synovial tissue but also by proliferation and neovascularization of cells lining the synovium. 40 TNF-a has been reported to be one of the primary angiogenic mediators derived from monocytes/macrophages obtained from rheumatoid synovial tissue 2 and treatment of patients with recombinant soluble TNF-a receptor has been associated with improvement in the symptoms of rheumatoid arthritis. 41 The expression levels of VCAM-1 have been demonstrated to be upregulated in rheumatoid synovium. 42, 43 Elevated levels of sVCAM-1 have been detected in the plasma and synovial uid from arthritic patients. 44, 45 Interestingly, the angiogenic potential of human rheumatoid synovial¯uid as measured in the rat corneal model could be attenuated with antibodies directed against VCAM-1.
14 These results suggest that the production of sVCAM-1 by TNF-a may play a prominent role in the progression of angiogenic, in¯ammatory diseases.
Conclusion
TNF-a-induced endothelial cell migration in vitro and angiogenesis in rat corneas in vivo were inhibited by antibodies or by a small peptide antagonist directed against the VCAM-1/a4 integrin adhesion pathway. These data support a mechanism by which TNF-a induces angiogenesis via the generation of sVCAM-1 which then acts through an a4 integrin receptor expressed on the endothelial cell surface. Our results extend the ®ndings of Koch et al.
14 implicating sVCAM-1 as an angiogenic mediator and strengthen the link between in¯ammatory cytokines, cellular adhesion, and angiogenesis. Angiogenesis induced by TNF-a is mediated by a4 integrins
